Halozyme Therapeutics Inc

NASDAQ:HALO

Earnings Call Analysis

Strong Growth in Q3 Financials

In the third quarter of 2024, the company reported an impressive 34% increase in total revenue, reaching $290.1 million, up from $216 million year-over-year. This significant growth was primarily driven by a 36% jump in royalty revenues, totaling $155.1 million, reflecting the robust performance of products like STARZ, LAC, VESCO, and VYVGART Hytrulo. The company's high-margin business model produced adjusted EBITDA growth of 60% to $183.6 million, showcasing their operational efficiency.

Raised Guidance Levels

Due to strong momentum, the company has revised its guidance for the fiscal year. Total revenue is now expected to be between $970 million to $1.020 billion, up from last year's $829 million, indicating growth of 17% to 23%. Specifically, collaboration revenues are projected to contribute between $130 million to $150 million, while product sales are anticipated at $290 million to $305 million. Royalty revenues are also expected to grow 23% to 26%, reaching $550 million to $565 million.

Continued Royalty Revenue Momentum

The contribution from key products has surpassed expectations, with subcutaneous applications becoming significant growth drivers. This includes an increase in royalties from products such as DARZALEX and FESCO. The company expects adjusted EBITDA to grow by 40% to 47%, amounting to $595 million to $625 million by year-end, up from $426 million last year.

Strategic Partnerships and Product Launches

The company’s strategy involves expanding its partnerships. Recently, Argenx expanded its collaboration by nominating four additional targets that could add up to $85 million in milestone payments. The growth in collaborations underscores the company's innovation in drug delivery technology, positioning it as a leader in enhanced, higher-volume subcutaneous delivery.

New Product Approvals and Market Expansion

Recent regulatory approvals for two major products, OCREVUS ZUNOVO and Tecentriq Hybreza, highlight the company's expanding market influence. Both approvals allow for subcutaneous administration, significantly reducing treatment times and enhancing patient accessibility. OCREVUS ZUNOVO has been projected to open up a $2 billion market opportunity, driving future revenue growth from the company's royalty base.

Financial Stability and Strong Cash Position

The company ended the quarter with a sturdy balance sheet, holding cash, cash equivalents, and marketable securities worth $666.3 million, an increase from $529 million in June 2024. This strong liquidity positions the company well for future investments and operational needs, while their net leverage ratio stands at 1.4x, with expectations for further reduction as EBITDA expands.

Future Revenue Expectations

Looking ahead, the company projects to exceed $1 billion in royalty revenue by 2027, bolstered by the expected uptake of recently approved drugs. With the extensive patent portfolio supporting its business model, the company is confident in its ability to sustain double-digit growth rates, setting a solid foundation for 2025 and beyond.

Conclusion: A Strong Performer in Drug Delivery

In summary, the company's robust Q3 performance, raised guidance, and strategic product launches emphasize its strong market position and growth potential. The focus on innovation in drug delivery technologies not only enhances patient access but also promises significant revenue streams through its expanding royalty base. Investors should consider these factors when evaluating the company's potential for long-term growth.

Earnings Call Transcript 2024-Q3

[Operator]

Good afternoon. My name is Jay, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Halozyme Third Quarter 2024 Financial and Operating Results Conference Call. [Operator Instructions] Please note, this event is being recorded. I'll now turn the call over to Tram Bu, Halozyme's Vice President of Investor Relations and Corporate Communications. Please go ahead.

[Tram Bui, executive]

Thank you, operator. Good afternoon, and welcome to our third quarter 2024 financial and operating results conference call. In addition to the press release issued today after the market closed, you could find a supplementary slide presentation that will be referenced during today's call in the Investor Relations section of our website.

Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer; who will provide an update on our business; and Nicole LaBrosse, our Chief Financial Officer, will review our financial results as well as our outlook.

On today's call, we will be making forward-looking statements as outlined on Slide 2. I would also refer you to our SEC filings for a full list of risks and uncertainties. During the call, both GAAP and non-GAAP financial measures will be discussed. Certain non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and slide presentation.

I will now turn the call over to Dr. Helen Torley.

[Helen Torley, executive]

Thank you, Tram, and good afternoon, everyone. Let me start on Slide 3. I am very pleased to report we delivered strong third quarter financial results with a 34% increase in total revenues to reach an all-time high of $290 million in the quarter. This was largely driven by royalty revenue, which increased 36% to another record amount of $155 million. This performance reflects the continued expansion and broadening of adoption of our enhanced drug delivery technology. with continued strong growth of DARZALEX subcutaneous Phesgo and VYVGART Hytrulo. Based on our strong year-to-date performance, we are raising our total revenue, our royalty revenue, adjusted EBITDA and non-GAAP earnings per share guidance ranges for the full year. .

Notably, this year, we now expect to deliver high double-digit revenue growth of 17% to 23% and an impressive adjusted EBITDA growth of 40% to 47%. Nicole will go into more detail on this in a moment. Operationally, it was also another strong quarter. Two current partners nominated new targets for ENHANZE under expanded licensing agreements, adding new revenue in terms of milestones and reinforcing the value of our leading drug delivery technology. We've also continued our focus on securing new enhanced deals and also new agreements for our small and our high-volume auto-injectors with discussions continuing and advancing. Roche, one of our most tenured partners gained 2 significant regulatory approvals with the FDA approval for Tecentriq subcutaneous with ENHANZE and for OCREVUS cutaneous with ENHANZE.

And adding to this, multiple partners continue to expand their geographic approvals and advance their clinical development programs. These achievements are key drivers of our current and future growth trajectory. They reinforce our leading position in rapid large volume subsidies drug delivery and illustrate the well-proven success and predictability of our platform technology.

I'll now move to Slide 4, and we'll provide some more details on these recent [indiscernible]. In September, we were delighted to announce 2 high anticipated partner approvals, which reinforce and has a track record of 100% Phase III to regulatory approval success. The U.S. approval of Roche's TECENTRIQ HYBREZA with ENHANZE represents the availability of the first and only subcutaneous anti-PDL1 cancer immunotherapy. Approval was granted for all of the adult IV Tecentriq indications with treatment delivered as an approximately 7-minute subcutaneous injection. Roche's also received U.S. approval of OCREVUS ZUNOVO with ENHANZE. Which is our 8 partnered product approval and further extended ENHANZE is reach into neurology.

With OCREVUS ZUNOVO, multiple sclerosis patients can now receive their treatment as a 10-minute subcutaneous injection given twice a year compared to a multi-hour treatment for the intravenous also given twice a year. This dramatic simplification of treatment also creates the opportunity for patients to receive their treatment outside an IV infusion facility potentially closer to their home. These 2 recent approvals add to the significant growth opportunity we have right in front of us, building on and adding to the recent European launches of Tecentriq and OCREVUS subcutaneous with ENHANZE.

Let me move now to the partner agreement expansions, [ ENHANZES vehicle ] standard for rapid subcutaneous large-volume drug delivery. This has been established over the last 10 years as a result of the strong safety track record and the unmatched history of global regulatory approvals and commercial success. This success is supporting productive conversations with existing partners who have experienced firsthand the success they can achieve with ENHANZE.

We are pleased that this has resulted in 5 new target nominations in the quarter. In early October, we announced that Argenx expanded their agreement for the exclusive license to ENHANZE by nominating 4 additional targets. Based on this expansion, Argenx has now exclusively licensed in [ hands ] for a total of 6 targets, including VYVGART Hytrulo. As part of the agreement, Argenx will make a $30 million payment to Halozyme for the 4 new targets. There are potential future milestone payments related to development progress, regulatory approvals and sales attainment of up to $85 million per new target. We are very excited to expand our relationship with Argenx who is an innovative leader in immunology. As their partner of choice for rapid large-volume [ Sotesdrug ] delivery, we appreciate their patient-centric mission that is so closely aligned with our own commitment to improving the lives of patients through our innovative drug delivery technologies.

In the quarter, Viv also expanded their existing global collaboration and licensing agreement, which gives them exclusive access to our ENHANZE drug delivery technology for 1 additional undisclosed target. Now with that overview, I'll move now to discuss the progress of our milestone and royalty generating subcutaneous commercial products, starting with Johnson & Johnson DARZALEX on Slide 5.

In the quarter, worldwide sales for DARZALEX increased almost 23% on an operational basis to represent the first asset in the J&J portfolio to reach $3 billion in a single quarter. DARZALEX growth was primarily driven by share gains of 4 points across all lines of therapy with 7.7 points of growth in frontline setting as well as continued market growth. With conversion to DARZALEX FASPRO with ENHANZE exceeding 90% share of sales in the United States and with very high conversion rates outside the United States. Subcutaneous DARZALEX is the driver of this remarkable continued strong DARZALEX growth. further expanding DARZALEX ethane's indications an opportunity during the quarter, J&J announced additional new approvals and regulatory submissions. U.S. and European approval were recently received for an additional indication for DARZALEX with ENHANZE in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplant in combination with bortezomib, lenalidomide and dexamethasone.

The company also announced the submission of a supplemental BLA to the Food and Drug Administration for approval of a new indication of DARZALEX FASPRO as part of a quadruplet regimen for the treatment of adult patients with newly diagnosed multiple myeloma for whom autologous stem cell transplant is deferred or who are ineligible.

With that, I'll now turn to Roche's Phesgo, which is shown on Slide 6. Phesgo, which is a fixed combination of Perjeta and Herceptin with ENHANZE continues to demonstrate excellent growth momentum. Sales increased 58% to CHF 1.2 billion for the first 9 months of 2024. Uptake remains strong as additional countries launch with 55 countries now launched. Conversion of Perjeta has also increased to 43% in those countries. Phesgo is on a strong trajectory and is well positioned to reach and exceed 50% conversion by 2026. Also shown in the slide is updated analyst revenue consensus for Phesgo, with the strong growth and momentum I've just discussed, Phesgo is now projected to become a $3.5 billion brand in 2028. As all of this $3.5 billion in sales represents subcutaneous sales on which Halozyme has paid a mid-single-digit royalty. Phesgo represents another strong growth opportunity for Halozyme. Moving now to additional highlights on Roche's 2 most recent launch products, which are shown on Slide 7.

I'll start with Tecentriq Hybreza. Following European approval in January of this year, we were very pleased that similarly to Europe, the U.S. approval was granted for all of the adult IV indications. Tecentriq Hybreza, co- formulated with ENHANZE allows for an approximately 7-minute subcunous injection compared to 30 to 60 minutes for the IV infusion. De mentalizing the opportunity, Roche reported eCentric revenue of CHF 2.7 billion for the first 9 months of 2024. The Analysts predict that tenth centric will achieve $5 billion in 2028. Roche's has stated that they expect the majority of the sales of subcutaneous Tecentriq will come from conversion of the intravenous distortion. Let me move now to Roche's OCREVUS ZUNOVO. I'm particularly excited for the U.S. launch following the Food and Drug Administration approval in September. This approval follows closely on the European approval, which occurred in June of this year. OCREVUS ZUNOVO with ENHANZE expands on reach in neurology and offers multiple sclerosis patients in treatment administration time of just 10 minutes via subcutaneous injection with ENHANZE which compares to multiple hours required for the IV infusion. The subcutaneous formulation offers patients all of the benefits that they expect from OCREVUS in terms of the strong clinical profile and every 6-month dosing.

While easing the administration burden of receiving treatment. OCREVUS revenue increased 9% to CHF 5 billion for the first 9 months of the year, driven by all regions. Roche's has commented on the recent quarterly call that they are confident that [indiscernible] formulation with ENHANZE will expand OCREVUS's footprint in the multiple sclerosis market and represent an incremental $2 billion sales opportunity. The availability of subcutaneous also makes it possible by opening up the treatment opportunity at smaller community hospitals as an example, making it easier for patients to travel to receive treatment. Which also sees an opportunity for patients to convert from IV OCREVUS ZUNOVO 2 to the subcutaneous version. Roche's has commented that they are seeing promising first signals regarding the uptake in the U.S., which is supporting market expansion. About 80% of the new starts on OCREVUS ZUNOVO are coming from patients who are new to brand and who are not switches from OCREVUS IV.

Let me move now to Argenx and VYVGART Hytrulo, which is shown on Slide 8. Argenx is VYVGART continues to experience strong momentum in its first indication of generalized [ Mycena gravis ]. Argenx recently commented that they expect subcutaneous VYVGART will grow in importance with patients, physicians and payers. We're pleased that subcutaneous VYVGART with ENHANZE is already expanding the market by bringing in new patients and providers to live guard with patients switching from oral medications to subcutaneous including patients who don't have easy access to an IV infusion center.

Moving now to chronic inflammatory demyelinating polyneuropathy. The second indication -- while the launch is recent, Argenx has commented that with the unmet medical need, they are happy to see high awareness for the subcutaneous option amongst patients and physicians. Organic expects to create fast and broad access for CIDP patients similar to what they accomplished in their launch in myasthenia gravis. We're also looking forward to the approval of a prefilled syringe for VYVGART Hytrulo with ENHANZE, which will introduce a more convenient administration option for patients with GMP and also CIDP. The preprefilled syringe filing has a PDUFA action date of April 10, 2025. Energenic has also continued to expand its presence in additional regions. Most recently, its BLA for efgartigimod subcutaneous with ENHANZE for JMG was approved in China, increasing number of approvals to more than 25 countries globally.

Given the strong launch of VYVGART, multiple analysts currently project total sales to reach almost $5 billion in 2028 for just the first 2 approved indications. We believe there is considerable opportunity to increase the total addressable market for VYVGART as argenx continues to advance its pipeline and the product strategy by expanding to additional indications over time. We're pleased to be supporting 2 registrational studies evaluating VYVGART Hytrulo with ENHANZE administered by prefilled syringe in thyroid eye disease, an indication where there is fairly high unmet need.

In addition, in October, Argenx initiated a Phase III study evaluating VYVGART Hytrulo with ENHANZE for ocular myasthenia gravis. And also recently, argenx initiated a Phase II trial in kidney transplant recipients with antibody-mediated rejection. Now beyond VYVGART Hytrulo, Argenx has a robust pipeline of multi-indication assets including [ mass pervert ] or ARGX-117. As an innovator committed to improving patients' lives, Argenx was at the forefront of recognizing the benefit of subcutaneous delivery. The early success of VYVGART Hytrulo is a strong proof point in the value proposition of ENHANZE-enabled subcutaneous delivery. And we are very pleased to have expanded our agreement with argenx from 2 to 6 nominations and to be their partner of choice for rapid large volume subcutaneous drug delivery.

Let me now move to Slide 9 for an update products that are awaiting regulatory approval and launch. I'll begin with Bristol-Myers Squibb, Nivolumab subcutaneous. Bristol received regulatory filing acceptance in the U.S. last quarter for Nivolumab subcutaneous with ENHANZE, with a PDUFA action date of December 29 of this year. The European submission is also under review. Once approved, this would represent our ninth approved product with ENHANZE. Nivolumab subcutaneous with ENHANZE has the potential to benefit both patients and physicians with a less than 5-minute treatment administration time. OPDIVO, which is the brand name for IV Nivolumab is currently $9 billion in annual sales. Bristol has stated that it projects that granted subcutaneous indications will represent 75% of the total sales. They also stated they expect to convert between 30% to 40% of the IV Nivolumab to subcutaneous Nivolumab. Johnson & Johnson's Amivantamab subcutaneous with ENHANZE is also pending regulatory approval and is currently under priority review with the FDA. Approval would represent our tenth launched partner product. Earlier this year, exciting data from the PALOMA-3 trial for Amivantamab subcutaneous was presented at ASCO. The presenters highlighted a fivefold reduction in infusion-related reactions as compared to the intravenous a fivefold reduction in treatment time. And also, they presented the results of an exploratory analysis, which revealed an improved overall survival rate for the subcutaneous treatment arm.

During their last earnings call, J&J highlighted that they believe Riverbend, which is a brand name for Amivantamab IV is 1 of the 3 largest underappreciated assets in their portfolio in terms of revenue projections versus what analysts are currently estimating for the back half of this decade. What is clearly exciting is that the 5 recently launched and soon to be launched products represent almost $35 billion in total brand opportunity according to analysts and company estimates. This represents an even larger opportunity than the DARZALEX subcutaneous and FASPRO opportunity where analyst projections are $20 billion in 2028. As Halozyme receives on average a mid-single-digit royalty and subcutaneous sales -- you can clearly see how these products will add significant revenue over the next years and result in our projecting to achieve greater than $1 billion in royalty revenue in 2027.

Let me now move to Slide 10, where I'll mention a few highlights on some of our future potential launch products. Bristol-Myers has continued to advance their Phase III study for Nivolumab plus Relatlimab with ENHANZE in first-line non-small cell lung cancer. The IV combination is already approved and has the brand name of [ Dulac ]. Takeda also continues to advance our Phase III study with TAK-881, their 20% AG product candidate, which is progressing in a Phase III trial for the treatment of primary immunodeficiency. With all of this continued strong growth of our approved product, the exciting launches that are just beginning and the regulatory and clinical advancements, we are well positioned to continue to deliver double-digit top and bottom line growth in the coming years. Let me now transition to Slide 11, and I'll make some comments on intellectual property. Our extensive patent estate supports the durability of our revenue streams, and we continue to take actions to extend and protect our IP portfolio. In June, we were granted a new patent for ENHANZE by the European Patent Office, which extended patent coverage of our technology in that region to March 6, 2029. This resulted in an update to our guidance. We currently have a similar pending reissue patent in the United States that we're confident will be granted.

We look forward to providing an updated financial outlook if that reissue patent is granted with similar claims. And as a pioneer in developing human hyaluronidases for subcutaneous administration of medicines, we were very excited to introduce our MDA's patent portfolio that broadly covers modified human high leronodates. Halozyme created the first soluble human high aromatase that was activate Neutrop, which we call ENHANZE. Notably, we did not stop there. We continue to innovate and experiment. And over many years and thousands and thousands of experiments, we created a large and comprehensive library of modifications, and we characterize those modifications. This groundbreaking work and other research projects created the technology protected by the MD's patents, which are distinct from the patents that cover the truncated human hyaluronidase that we license as our ENHANZE technology. Now why are we discussing the MD's portfolio? No. There really are 2 key reasons.

Firstly, we've recently been issued multiple new end patents. Bringing the total granted and pending the to nearly 100, and we wanted to distinguish the MDA patents from ENHANZE to avoid any confusion. Secondly, as an intellectual property licensor, we always are looking for new opportunities to commercialize our discoveries and to enable others to bring forward new solutions and therapies that help patients. The ENHANZE technology is the derisked gold standard for conversion of IV therapies to subcutaneous administration. However, we do recognize that not every drug and biologic supplier might be able to or select to use in hand. But they do wish to utilize or or utilizing Halozyme pioneering modified high laronadies intellectual property. It's in those cases that the MDA patents are now available for license and would open up new opportunities for Halozyme that do not impact our ENHANZE business.

I'll now hand the call over to Nicole, who will discuss our financial results in more detail.

[Nicole LaBrosse, executive]

Thank you, Helen. I'll begin with an overview of our third quarter performance and then review the increased guidance ranges for 2024 that are resulting from our strong progress. Our robust financial results for the third quarter exceeded expectations. Due to higher revenues from royalties and collaboration revenues in the quarter. The result is an impressive 34% increase in total revenue from prior year. with adjusted EBITDA and non-GAAP earnings per share growth outpacing our top line growth at [ 60% ] and 69%, respectively. A clear demonstration of the significant leverage we have with our high-margin business model. Let me now turn to Slide 12 for our detailed financial results for the third quarter.

Revenue grew 34% to $290.1 million compared to $216 million in the prior year period. Royalty revenues for the quarter were $155.1 million an increase of 36% compared to $114.4 million in the prior year period. The continued growth of subcutaneous STARZ LAC, VESCO and VYVGART Hytrulo were the main drivers of our royalty revenue growth in the quarter. The contribution from all 3 products exceeded our expectations for the quarter, resulting in an increase in guidance for the full year. Collaboration revenues for the quarter were $48.4 million compared to $15 million in the prior year period. The performance exceeded our expectations for the quarter due to the meaningful expansion of our Argenx collaboration. Research and development expenses were $18.5 million compared to $17.3 million in the prior year period. The increase was primarily due to increased compensation expense.

Selling, general and administrative expenses were $41.2 million in the quarter. Up from $35.3 million in the prior year period, primarily due to increased compensation expense and consulting and professional service fees. Adjusted EBITDA increased 60% to $183.6 million from $114.9 million last year. GAAP diluted earnings per share was $1.05, and non-GAAP diluted earnings per share was $1.27. This is compared with GAAP diluted earnings per share of $0.61 and non-GAAP diluted earnings per share of $0.75 in the third quarter of 2023. We maintained a strong balance sheet with cash, cash equivalents and marketable securities at $666.3 million on September 30, 2024.

Compared to $529 million on June 30, 2024. The increase was primarily a result of cash generated from operations. Our net leverage ratio was 1.4x at the end of the quarter. and we still expect to reduce our net leverage ratio as EBITDA continues to grow. As a result of our strong year-to-date performance and expectations for continued momentum in the fourth quarter, we are raising our guidance ranges for the full year as shown on Slide 13. We now expect total revenue of $970 million to [ $1.020 billion ]. an increase year-over-year from $829 million, which represents an increase of 17% to 23% over 2023. This includes our expectation that collaboration revenue will contribute $130 million to $150 million, and product sales will contribute $290 million to $305 million for the full year. We expect royalty revenues of $550 million to $565 million, an increase year-over-year from $448 million, which represents 23% to 26% growth over 2023. The increase in our expectation for the year is due to the strong performance of subcutaneous STARLUX, FESCO and VYVGART Hytrulo. We expect adjusted EBITDA of $595 million to $625 million, an increase from $426 million in 2023, a 40% to 47% year-over-year increase. and we expect non-GAAP diluted EPS of $4 to $4.20, an increase year-over-year from $2.77, which is a 44% to 52% increase over 2023.

With that, I'll now turn the call back over to Helen.

[Helen Torley, executive]

Thank you, Nicole. Our strong year-to-date performance is a reflection of the execution of our strategy and the power of our durable high-growth business models. This resulted in a meaningful rate in our expectations and our financial guidance for the year, resulting in impressive year-over-year growth and setting us up for a strong start to 2025. We have multiple drivers that will support our continued growth, including an exciting series of launches that are just beginning or soon to commence. I'd like to close by recognizing and thanking the Halozyme team and all of our collaborators whose continued dedication and performance has made this such a remarkable quarter and year. Operator, we are now ready to open the call for questions. .

[Operator]

[Operator Instructions] Your first question comes from the line of Vikram Purohit of Morgan Stanley.

[Morgan Gryga, analyst]

This is Morgan on for Vikram. So one for us on the OCREVUS and Tecentriq recent launches, although it's early, what's your current view on subcu conversion for these products and how that could ramp in the coming quarters and what that may look like long term on a steady-state basis?

[Helen Torley, executive]

Yes. Thanks, Morgan. We'll start with OCREVUS. And I think it's important to note there, and Roche reiterated this on their quarterly call just a week or so ago. Their goal with the subcu is not to immediately convert the IV to subcu. So it's not a conversion strategy. It's very much a market growth strategy. where they see the availability of subcutaneous as allowing more treatment centers and more throughput of patients at infusion suites community hospitals because of the much shorter treatment time with subcutaneous the easier approach to subcu, which doesn't require as much infrastructure Indeed, they commented that they see the availability of subcu will expand the Ocrevus at market by about $2 billion. So initially for Ocrevus, field force will be very much focused on getting new prescribers and helping those new prescribers set up and start using Ocrevus. If I move to Tecentriq, obviously, Tecentriq continuing to perform well in key tumor indications as an IV given over 30 to 60 minutes. Within that, there are patients who are receiving Tecentriq as an example, as monotherapy or for whom they're on a complex regimen where the want to have a shortened regimen.

And in that instance, there's going to very much be a focused to convert those patients from the IV to the subcu because of the much simpler regimen. And so we are going to see good conversion focus with Tecentriq. Market growth for OCREVUS. Roche has not given out any numbers as to where they the conversion. Our approach has generally been to look at the success they had with Herceptin subcu in Europe, which got to 60% share of volume and then to have a range around that depending on is the company driving for that subcu conversion. So particularly for Tecentriq, I'd think about it in those terms.

[Operator]

Your next question comes from the line of Brendan Smith of TD Cowen.

[Brendan Smith, analyst]

All right. Congrats on the following quarter. I wanted to first ask, Phil, kind of piggyback on that last question about Ocrevus a subcu. You called out the language from Roche about that $2 billion just to kind of better understand that or maybe contextualize it a bit. I mean if consensus for peak sales is around $9 billion, $10 billion there, that might suggest only about 20% share of the subcu. Is that maybe the right way to think about that? Or is this -- or is this $2 billion really kind of new-to-brand patients that would be in addition to IV to subcu switches? And then maybe just really quickly on the Wave 4 pipeline. Are you able to give us any sense of at what point we might learn about the additional Roche and Chugai drugs, just whether target indication like after Phase II data or something like that? Just trying to understand when we might start focusing more on that wave?

[Helen Torley, executive]

Yes. Thanks, Brendan, and thanks for asking that question because I do think the way Roche has been talking about it has led people to be a little bit confused. So there's going to be a market expansion, which is on top of the IV opportunity. And so if it's at $9 billion -- my view is this is going to take the total growth in the next several years to be $11 billion so you do add on the additional $2 billion. But the original IV sales of the $9 billion will we strongly believe be converted. When you think about what the difference is going to be for a patient instead of 3.5 hours to 5.5 hours in an infusion suite, it's going to be 30 minutes in an infusion Sweden.

So, there is also going to be that conversion of the IV to subcu. I think what you're going to see is it's going to be phased. The initial launch focus is on expanding the market. And over time, we're going to see the conversion begin and grow as well. But when we hearing from Roche. They very much want to highlight this is not just a cannibalization opportunity. So don't think about the pie staying the same size it is today. the pie is going to get bigger and then he's also going to be the opportunity to convert that bigger pie to be more subcu sales. Just on that, they also made a comment on their call that they are seeing already the strategy work in the U.S., obviously, very recent launch in the U.S., but they're seeing that 80% of new starts on Ocrevus Inuvo are new to brand. So very much supporting that approach they have where they don't want to cannibalize their IV sales. They want to further expand their opportunity while they also will be able to, over time, get that subcu conversion too. With regard to the specific Roche and Chugai products that are listed on our portfolio. Unfortunately, until the partners want to discuss exactly what those indications are and announce their plans for them, we are unable to discuss any further. So I can't give any updates at this time.

[Operator]

Your next question comes from the line of Mike DiFiore of Evercore ISI.

[Michael DiFiore, analyst]

Congrats on the solid quarter. Two for me. First question is any status update regarding your expectations for new collaboration deals to be made before the end of the year? And I have a follow-up.

[Helen Torley, executive]

All right. Thanks, Mike, for that. You saw probably that we have provided our guidance for the year on the collaboration $130 million to $150 million. And we're very pleased with the progress we've made here, obviously, strong contributions from the expanding the agreement with argenx in particular, in the quarter. I will say we are not letting our feet off the gas pedal, and we're remaining very focused gaining new deals and additional new nominations as we close out 2024. But if you do take a look at our guidance, you can see where the range we're predicting based on what we have line of sight on today. In that $130 million to $150 million range.

[Michael DiFiore, analyst]

Got it. Got it. And my follow-up question is regarding MDASE considering that the MDASE licensees are not exclusive and won't involve Halozyme support services or API supply, as you previously noted, how will licensees manage development and regulatory challenges typically -- that are typically supported in traditional enhanced partnerships? And how might this affect MDASE's adoption and commercial success compared to an end?

[Helen Torley, executive]

Yes. I will be clear and say we do expect that the vast majority of companies are going to want to and be able to work with ENHANZE. And so as we think about where we're going to be focusing and our growth is going to come from, it's going to be new partners and expanded partnerships related to ENHANZE. But as we pointed out, there may be instances where somebody is unable to or for some reason, doesn't want to work with ENHANZE, but they are utilizing or modified hyaluronidase IP. We are in that instance only going to grant them a license, as you point out. Now we obviously don't have a modified hyaluronidase VP product substance. So that company will have to do what we did for the last 10 years, which is identify how to develop a product, engage with the regulatory authorities, start developing that safety database we have to demonstrate the product safe and effective, but we would not propose to help them because we are going to be continuing to support our current ENHANZE partners.

But we will license the IP because going to be using their MDASE, they modified the hyaluronidase for the same purpose as it has. And obviously, that's where the value of our IP is being realized.

[Operator]

Your next question comes from the line of Jason Butler of Citizens JMP.

[Jason Butler, analyst]

Just one on VYVGART Hytrulo and the prefilled syringe. Can you maybe just speak to the progress there with FDA and how you work with other collaborators or other products has inputted into this regulatory process?

[Helen Torley, executive]

Yes. Thanks, Jason. If you listen to the call today, as we did Argenx we provided the update and just summarize that they are expecting a PDUFA action date that is going to be in April. We don't have information that we can share with regard to that. But we are excited that they are obviously progressing with that in studies that are ongoing, both in thyroid eye disease and other indications now. Again, this really has been work that we have done, obviously, in providing the ENHANZE that prefilled syringe work. But I will say Argenx has been lead with regard to the actual mechanical work in that. We obviously continue to advise on the formulation of ENHANZE. And so we don't have any information other than that I can share, Jason.

[Operator]

Your next question comes from the line of Karen Johnson of Goldman Sachs.

[Unknown Analyst]

Maybe could you expand a little bit on the primary drivers? Is that increase in royalty revenues? You mentioned the products that are driving it, but I'm curious if it was additional indications within DARZALEX, et cetera, better than version of the key products or anything else that you could kind of point to? And then could you also talk a little bit about where you stand on potential auto injector partnership deals. We haven't really seen anything yet. I'm just curious if there's any additional work you're doing to kind of prove out that technology?

[Helen Torley, executive]

Yes. small bits of color we can bring based on what our partners have stated publicly. I think we can for DARZALEX, they reported a very strong quarter, obviously, with a great sequential and year-over-year growth. And what they are talking about is just continued expansion of 4 points of share gains across all indications and 7 points of share gain in the front line. And recall the front line is actually the largest population of multipe myeloma patients, and those are the patients who stay on therapy the longest. And so I really think the growth that we've seen over the last several years has been fully enabled by the availability of subcu to expand as they were getting new indications into that frontline setting.

So that's really, I think, where it's very exciting. If we turn to VYVGART Hytrulo based on the call this morning, what we heard the majority of the revenue is obviously still coming from the GMG indication where they're continuing to see broadening adoption of VYVGART and also VYVGART with VYVGART Hytrulo really helping move into that early line of therapy. So that is on a strong trajectory. What has begun to impact with VYVGART Hytrulo is the CIDP indication. Specific comments were made about the fact that 300 patients on therapy, many of whom who came on in September, really occurring after the payer policies were in place.

And so that actually bodes very well for continued growth is those patients that will be reflected as a full quarter in the next quarter. And so those are some of the key drivers. I'd say for FESCO, it's just continuing on that very nice trajectory that we've as there's just growing recognition of what this means for patients to be able to have just the more simpler regimen and allow them to get back to their lives. So in summary, a mix of new indications, strong execution by the partners and the availability of subcu to really penetrate into earlier lines of where patients tend to stay on therapy longer.

[Unknown Analyst]

And then on the auto-injector side?

[Helen Torley, executive]

Oh, sorry, on the auto injectors, I mention on the culture and we are continuing in discussions both with the high-volume auto-injector and also small volume auto-injector. Similarly, 2 comments I made on the enhanced -- there just always is a process we go through as the companies go through their technical evaluation process and then their decision process. So we're moving our way through those processes with those companies. And so no updates on that today. but continuing to make progress, and that still remain very confident we're going to be signing and announcing deals.

[Operator]

Your next question comes from the line of Mitchell Kapoor of H.C. Wainwright.

[Mitchell Kapoor, analyst]

Just wanted to know a little bit more about the MDA platform opportunity. Can you just give a little context to how big or narrow of an opportunity this might be based on how many types of opportunities might be out there for this when you do have the ENHANZE platform and the eligible partners that were likely focused on that side of the business or the BD partnerships?

[Helen Torley, executive]

Yes. Thanks, Mitch. And what we've talked about is the fact that we do anticipate ENHANZE will continue to be what people will come and want to license. It's a gold standard. It's the most regulatory and commercially derisked -- so that is where our primary focus is. But we are aware that there are companies who may be considering developing in modified hyaluronidase. And in that instance, they may not want to work with ENHANZE or they may not be able to work with ENHANZE, but have chosen this modified hyaluronidase. But if they're using a modified hyaluronidase, we believe they will be using some of our modified hyaluronidase IP. And that's why we have made these licenses available to them. So we don't think this is in terms of the number of deals going to be like we do with ENHANZE, and we're talking about new partners with the frequency of which we've done over the years, Mitch. But for anyone who is developing or thinking about developing a drug with a modified hyaluronidase, that going to be the opportunity for us. It's an emerging field. And so we haven't -- we can't really comment on how many people we think will want to do that. But the great news is it's another growth driver for us if companies are developing modified hyaluronidase days subcu drugs copying what we have been doing with ENHANZE.

[Operator]

Your next question comes from the line of Mohit Bansal of Wells Fargo.

[Mohit Bansal, analyst]

I have 2 questions. So 1 is -- how should we think about your guidance update philosophy going forward? Because I understand that you'll be providing guidance to '25 as next year rolls over. But should we be expecting updates for subsequent years as well as the expectations change? That's number one. And number two, for the MDASE platform, how differentiated it is from your ENHANZE platform? I'm asking from the point of view of your existing partners who have exclusive licensing with certain products. If it kind of infringes upon that, what gives you comfort that your existing partners would be fine with that?

[Helen Torley, executive]

Yes. I'll ask Nicole to comment on your question on the guidance, and I'll talk about MDASE.

[Nicole LaBrosse, executive]

Yes. Thanks for the question, hi. So from a guidance perspective, today, we are focused on the third quarter results and the full year updated guidance, which we're really excited to raised for top line and bottom line for the full year. And you saw we do republish our 5-year projections. Those are unchanged at the moment. but we continue to evaluate those in the new year. We'll give more line of sight and color into our updated expectations for 2025.

[Helen Torley, executive]

All right. And maybe I'll take a step back and just say, we talked about all of the experiments that we did and the experiments that we did on the human hyaluronidase area. And we came up with ENHANZE that we patented and that's a truncated human hyaluronidase, but we also did lots of experiments thousands and thousands of experiments on different structures of hyaluronidases and we called those are modified hyaluronidase. So ENHANZE has got 1 structure, the modified hyaluronidases have different structure from ENHANZE. And when we have licensed in hands, we are only licensing the IP to structure and the activities that are related to that specific ENHANZE structure, Mohit.

So that's why our partners will not -- are not upset or surprised or anything because they're totally different products and patent portfolios firstly. Now our ENHANZE partners do not need unlikely to want the MDASE portfolio because they have in hand. -- which does what it needs to do, which is this delivery of drugs high-volume rapid subcu delivery. But there are some people and partners and makers of drugs and biologics who perhaps can't work in ENHANZE or don't want to work and ENHANZE. And have chosen or will choose to work in a modified hyaluronidase. And what we wanted everyone to recognize is because of our pioneering work in this area, we have actually got an extensive patent portfolio that covers many modified hyaluronidase. And so for those companies, if they want to develop a modified hyaluronidase for doing the same thing as ENHANZE, which is the rapid large volume. So delivery, we wanted to make them aware that we are open and willing to license our patents that relate to the modified hyaluronidase it is. So it's a different product. It's a different structure but Halozyme was really the pioneer of making of making these new offerings that have enabled such an important advancement for patients. So let me just check in and see, did that clarify for you the difference between these 2?

[Mohit Bansal, analyst]

Very helpful. Thank you very much, Helen and Nicole.

[Helen Torley, executive]

Thank you.

[Operator]

Your next question comes from the line of Jessica Fye of JPMorgan.

[Na Sun, analyst]

This is Na Sun on for Jessica Fye. Congratulations on a strong quarter. My question goes back to DAS. I think can you just give us examples of how -- what case would a partner be unable to work with ENHANZE? And I think I've always thought about ENHANZE giving exclusive targets as a sort of defensive or how it's attractive for a defensive for its partners. So for days, wouldn't it give sort of like escape hatch, if you will, for competitors? And then secondly, I noticed that for the collaboration revenue guidance the top range came down a little bit. Can you just talk about a little bit like what is driving that?

[Helen Torley, executive]

Yes. So with regard to the situation where people couldn't work with ENHANZE, and I think it's a great question. You're quite right. Because we do the targets, if somebody wasn't able to work with us because we had already licensed an exclusive target, they might choose to work with a modified hyaluronidase. What we are doing here, however, is not enabling any partner to work and develop a modified hyaluronidase subcu enabled drug against that target. We are simply because we're not supporting them from a clinical development perspective, and we're also at not supplying the API. We are simply making them aware that if they want to go then that path, we have got strong IP in that area that is available for license. And this is why as we have converted and shared this approach with our current partners, we have really received no pushback or concerns that have been voiced on it.

Because we're not enabling and supporting the development of drugs that are doing anything against the license of ENHANZE. We are simply recognizing and seeking to create the value for Halozyme from our inventions that were done all those years ago related to the modified hyaluronidases. So I hope that clarified that. And in terms of the guidance ranges, yes, we are where we sit today, we've got a line of sight to $130 million to $150 million. We are continuing, as I mentioned earlier, to work hard to gain new deals and additional new nominations, but that was our best estimate based on where we are today for how the year is going to end. We certainly are going to be nicely above [ $130 millions ] in terms of collaborations. And so we're definitely fully in line with our original guidance. just tightened the range a little.

[Operator]

Your last question comes from the line of David Risinger of Leerink Partners.

[David Risinger, analyst]

Thanks very much. my key questions have been asked. So I just wanted to ask about product sales. So if you could just educate a little bit more, Helen with respect to why product sales are flattish in 2024? And then why they are expected to grow by 50% over the next 4 years. So I see your 2028 target for revenue is up about 50% from $300 million this year to roughly $450 million in [ '28 ].

[Helen Torley, executive]

Yes, that is a great question, and I'm going to pass over to Nicole.

[Nicole LaBrosse, executive]

Yes. Thanks, David. So in product sales, what you see in product sales are One, the products that we sell to our collaboration partners to our API in our devices where we've talked about historically, those can be lumpy quarter-over-quarter. We are making investments to have a lower-cost API for our partners. So over the longer term, that revenue stream will actually decline for us because as we make lower cost materials that gets passed on to our partners in savings. So that is one of the drivers in product sales. And then also we have our proprietary product sales. Those are the sales that annually year-over-year are increasing and also trending this year in line with our expectations for the full year. I will point out that products our proprietary product sales, you saw a slight decrease in sequential quarters in the third quarter, and that's due to a seasonality that we historically in the third quarter, where we do see a dip in demand in the summer months, and that is a part of our plans, and you'll see that in the results for the third quarter.

[Operator]

With no further questions, this concludes our Q&A session. And this also concludes today's conference call. You may now disconnect.